Jim Simons Bristol Myers Squibb CO Transaction History

Renaissance Technologies LLC

$70.6 Billion
Q3 2025

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Renaissance Technologies LLC holds 3,667,689 shares of BMY stock, worth $172 Million. This represents 0.23% of its overall portfolio holdings.

Number of Shares

3,667,689

Previous 3,481,133 5.36%

Holding current value

$172 Million

Previous $161 Million 2.65%

% of portfolio

0.23%

Previous 0.23%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	BUY	$43.31 - $48.98 $8.08 Million - $9.14 Million	186,556 Added 5.36%	3,667,689 $165 Million
Q2 2025 Aug 13, 2025	BUY	$44.12 - $59.6 $62.1 Million - $83.9 Million	1,407,000 Added 67.84%	3,481,133 $161 Million
Q1 2025 May 14, 2025	BUY	$53.9 - $63.11 $54.6 Million - $64 Million	1,013,600 Added 95.57%	2,074,133 $127 Million
Q4 2024 Feb 13, 2025	BUY	$51.92 - $59.94 $7.89 Million - $9.11 Million	151,995 Added 16.73%	1,060,533 $60 Million
Q3 2024 Nov 13, 2024	BUY	$39.66 - $51.75 $36 Million - $47 Million	908,538 New	908,538 $47 Million

Q4 2023 Feb 13, 2024	BUY	$48.48 - $57.85 $68 Million - $81.2 Million	1,403,312 Added 136.4%	2,432,166 $125 Million
Q3 2023 Nov 14, 2023	SELL	$57.89 - $64.73 $10.5 Million - $11.7 Million	-180,546 Reduced 14.93%	1,028,854 $59.7 Million
Q2 2023 Aug 11, 2023	BUY	$63.71 - $70.74 $4.15 Million - $4.61 Million	65,100 Added 5.69%	1,209,400 $77.3 Million
Q1 2023 May 12, 2023	BUY	$65.71 - $74.53 $32 Million - $36.3 Million	487,100 Added 74.12%	1,144,300 $79.3 Million
Q4 2022 Feb 13, 2023	BUY	$68.48 - $81.09 $45 Million - $53.3 Million	657,200 New	657,200 $47.3 Million
Q2 2022 Aug 12, 2022	SELL	$72.62 - $79.98 $132 Million - $145 Million	-1,811,314 Reduced 68.78%	822,018 $63.3 Million
Q1 2022 May 13, 2022	SELL	$61.48 - $73.72 $148 Million - $177 Million	-2,407,454 Reduced 47.76%	2,633,332 $192 Million
Q4 2021 Feb 11, 2022	SELL	$53.63 - $62.52 $112 Million - $130 Million	-2,080,139 Reduced 29.21%	5,040,786 $314 Million
Q3 2021 Nov 12, 2021	SELL	$59.17 - $69.31 $10.9 Million - $12.8 Million	-185,000 Reduced 2.53%	7,120,925 $421 Million
Q2 2021 Aug 13, 2021	BUY	$61.91 - $67.42 $20.7 Million - $22.5 Million	333,738 Added 4.79%	7,305,925 $488 Million
Q1 2021 May 13, 2021	SELL	$59.34 - $66.74 $683 Million - $768 Million	-11,508,443 Reduced 62.27%	6,972,187 $440 Million
Q4 2020 Feb 10, 2021	SELL	$57.74 - $65.43 $698 Million - $791 Million	-12,095,797 Reduced 39.56%	18,480,630 $1.15 Billion
Q3 2020 Nov 13, 2020	SELL	$57.43 - $63.64 $742 Million - $822 Million	-12,920,704 Reduced 29.7%	30,576,427 $1.84 Billion
Q2 2020 Aug 13, 2020	SELL	$54.82 - $64.09 $1.23 Billion - $1.44 Billion	-22,494,980 Reduced 34.09%	43,497,131 $2.56 Billion
Q1 2020 May 14, 2020	BUY	$46.4 - $67.43 $268 Million - $390 Million	5,781,450 Added 9.6%	65,992,111 $3.68 Billion
Q4 2019 Feb 13, 2020	BUY	$49.21 - $64.19 $1.35 Billion - $1.76 Billion	27,452,891 Added 83.81%	60,210,661 $3.86 Billion
Q3 2019 Nov 13, 2019	BUY	$42.77 - $50.71 $516 Million - $612 Million	12,059,163 Added 58.26%	32,757,770 $1.66 Billion
Q2 2019 Aug 12, 2019	BUY	$44.62 - $49.34 $372 Million - $412 Million	8,347,432 Added 67.58%	20,698,607 $939 Million
Q1 2019 May 14, 2019	BUY	$45.12 - $53.8 $244 Million - $291 Million	5,404,300 Added 77.79%	12,351,175 $589 Million
Q4 2018 Feb 13, 2019	BUY	$48.76 - $63.23 $339 Million - $439 Million	6,946,875 New	6,946,875 $361 Million

Others Institutions Holding BMY

# of Institutions

2,683

Shares Held

1.58B

Call Options Held

28.2M

Put Options Held

28.4M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $99.5B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account